Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Ludotadipep in Metastatic Castration-resistant Prostate Cancer
NCT05458544Phase 2Recruiting
- Sponsor
- FutureChem Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Jun 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of Ludotadipep in metastatic castration-resistant prostate cancer (mCRPC), sponsored by FutureChem Co., Ltd.. Started Sep 2022; status: recruiting.
02
Drugs
Ludotadipep
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05458544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05458544.